October
Curia Wisconsin, Inc. (PDF) (October 1, 2024)
Fresenius Kabi USA, LLC (PDF) (October 1, 2024)
September
Theodore S. Wright Jr., M.D.; Decision and Order (PDF) (September 27, 2024)
Wagner Gervais, P.A.; Decision and Order (PDF) (September 27, 2024)
Lawrence Rudolph, D.M.D.; Decision and Order (PDF) (September 27, 2024)
Adam L. Larson, M.D.; Decision and Order (PDF) (September 27, 2024)
Michael Fletcher, M.D.; Decision and Order (PDF) (September 27, 2024)
Charles Sangmoah, P.A.; Decision and Order (PDF) (September 27, 2024)
Curium US LLC (PDF) (September 25, 2024)
Proposed Amendment: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (PDF) (September 17, 2024)
George D. Gowder, III, M.D.; Decision and Order (PDF) (September 17, 2024)
Chemtos, LLC (PDF) (September 17, 2024)
Eli-Elsohly Laboratories (PDF) (September 17, 2024)
Mary A. Vreeke, M.D.; Decision and Order (PDF) (September 16, 2024)
Awesome Care Pharmacy, Inc.; Decision and Order (PDF) (September 16, 2024)
Purisys, LLC (PDF) (September 16, 2024)
Bright Green Corporation (PDF) (September 6, 2024)
Biopharmaceutical Research Company (PDF) (September 6, 2024)
Cambridge Isotope Laboratories, Inc. (PDF) (September 6, 2024)
Final Order: Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2024 (PDF) (September 5, 2024)
Samirkumar Shah, M.D.; Decision and Order (PDF) (September 4, 2024)
Chattem Chemicals (PDF) (September 4, 2024)
Bright Green Corporation (PDF) (September 4, 2024)
Continuus Pharmaceuticals (PDF) (September 4, 2024)
Catalent CTS, LLC (PDF) (September 4, 2024)
Benuvia Operations, LLC (PDF) (September 4, 2024)
Indivior Inc. (PDF) (September 4, 2024)
Amneal Complex Products Research LLC (PDF) (September 4, 2024)
Chattem Chemicals, Inc. (PDF) (September 4, 2024)
Biopharmaceutical Research Company (PDF) (September 4, 2024)
Cambridge Isotope Laboratories, Inc. (PDF) (September 4, 2024)
Fisher Clinical Services, Inc. (PDF) (September 4, 2024)
Caligor Coghlan Pharma Services (PDF) (September 4, 2024)
Cambrex High Point, Inc (PDF) (September 4, 2024)
Stephen McCarthy, P.A.; Decision and Order (PDF) (September 3, 2024)
August
Proposed Rule: Rescheduling of Marijuana (PDF) (August 29, 2024)
60-Day Notice: Exempt Chemical Preparations Under the Controlled Substance Act (PDF) (August 23, 2024)
Final Rule: Placement of Zuranolone in Schedule IV (PDF) (August 14, 2024)
Robert Rowen, M.D.; Decision and Order (PDF) (August 14, 2024)
Irene Kimura, M.D.; Decision and Order (PDF) (August 14, 2024)
Thomas M. Fausset, O.D.; Decision and Order (PDF) (August 14, 2024)
Michael L. Brodie, M.D.; Decision and Order (PDF) (August 14, 2024)
Stephen Matthews, M.D.; Decision and Order (PDF) (August 9, 2024)
Experic LLC (PDF) (August 8, 2024)
Cambrex High Point, Inc. (PDF) (August 8, 2024)
AMPAC Fine Chemicals, LLC (PDF) (August 8, 2024)
Cambrex Charles City (PDF) (August 8, 2024)
Catalent Greenville, Inc. (PDF) (August 8, 2024)
Benuvia Operations, LLC (PDF) (August 8, 2024)
VICI Health Sciences, LLC (PDF) (August 8, 2024)
Cerilliant Corporation (PDF) (August 8, 2024)
July
Temporary Scheduling Order: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I (PDF) (July 29, 2024)
Galephar Pharmaceutical Research Inc. (PDF) (July 29, 2024)
Catalent Pharma Solutions, LLC (PDF) (July 29, 2024)
Cerilliant Corporation (PDF) (July 29, 2024)
Deron Kovac, DMD; Decision and Order (PDF) (July 24, 2024)
Donna Winingham, MD; Decision and Order (PDF) (July 24, 2024)
Carrie L. Madej, DO; Decision and Order (PDF) (July 24, 2024)
John Qian, MD; Decision and Order (PDF) (July 24, 2024)
60-Day Notice; Extension: Drug Use Statement (PDF) (July 19, 2024)
Curia Missouri Inc. (PDF) (July 8, 2024)
S&B Pharma LLC DBA Norac Pharma (PDF) (July 8, 2024)
Arizona Department of Corrections (PDF) (July 8, 2024)
June
Michael Gore, P.A.; Decision and Order (PDF) (June 28, 2024)
Lisa Jones, N.P.; Decision and Order (PDF) (June 28, 2024)
Jeffrey Pollock, P.A.; Decision and Order (PDF) (June 28, 2024)
Abdul Naushad, M.D.; Decision and Order (PDF) (June 28, 2024)
Arash M. Padidar, M.D.; Decision and Order (PDF) (June 28, 2024)
AndersonBrecon Inc. DBA PCI Pharma Services (PDF) (June 17, 2024)
Lily's Eden Garden Farms Corporation (PDF) (June 17, 2024)
Coconut Grove Pharmacy; Decision and Order (PDF) (June 13, 2024)
American Radiolabeled Chem (PDF) (June 7, 2024)
Usona Institute (PDF) (June 7, 2024)
Veranova, L.P. (PDF) (June 7, 2024)
Unither Manufacturing LLC (PDF) (June 7, 2024)
May
ANI Pharmaceuticals, Inc. (PDF) (May 31, 2024)
Royal Emerald Pharmaceuticals (PDF) (May 31, 2024)
United States Pharmacopeial Convention (PDF) (May 31, 2024)
Revvity, Inc. (PDF) (May 30, 2024)
Almac Clinical Services Incorporate (PDF) (May 30, 2024)
Vici Health Sciences, LLC (PDF) (May 30, 2024)
VA Cooperative Studies Program (PDF) (May 30, 2024)
Royal Emerald Pharmaceuticals (PDF) (May 30, 2024)
Quagen Pharmaceuticals LLC (PDF) (May 30, 2024)
Veranova, L.P. (PDF) (May 30, 2024)
ANI Pharmaceuticals Inc. (PDF) (May 30, 2024)
Chemtos, LLC (PDF) (May 30, 2024)
AMPAC Fine Chemicals Virginia LLC (PDF) (May 30, 2024)
Skalar Pharma, LLC (PDF) (May 30, 2024)
Pharmaron Manufacturing Services (US) LLC; Correction (PDF) (May 29, 2024)
Proposed Rule: Rescheduling of Marijuana (PDF) (May 21, 2024)
Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (May 15, 2024)
Curia New York, Inc. (PDF) (May 9, 2024)
Veranova, L.P. (PDF) (May 9, 2024)
Wedgewood Village Pharmacy, LLC (PDF) (May 8, 2024)
Pisgah Laboratories Inc. (PDF) (May 6, 2024)
Entheogen Pharmaceuticals Inc. (PDF) (May 6, 2024)
Lipomed (PDF) (May 6, 2024)
Research Triangle Institute (PDF) (May 6, 2024)
Restek Corporation (PDF) (May 6, 2024)
NSI Lab Solutions, Inc. (PDF) (May 6, 2024)
AndersonBrecon dba PCI Pharma Services; Correction (PDF) (May 6, 2024)
Pharmaron Manufacturing Services (US) LLC (PDF) (May 6, 2024)
AndersonBrecon dba PCI Pharma Services (PDF) (May 6, 2024)
- REGISTRATION
- REPORTING
- RESOURCES
- CONTACT US
- PRIVACY NOTICE
- GET EMAIL UPDATES
Get Email Updates
The United States Department of Justice
You are now leaving a Department of Justice Web site.
You are about to access:
The Department of Justice does not endorse the organizations or views represented by this site and takes no responsibility for, and exercises no control over, the accuracy, accessibility, copyright or trademark compliance or legality of the material contained on this site.
Thank you for visiting our site.